Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    9-Me-BC (9-Methyl-β-carboline) molecular structure

    9-Me-BC (9-Methyl-β-carboline)

    NootropicsPreclinical

    Also known as: 9-Me-BC, 9-MBC, 9mebc, 9-mebc, 9-MeBC, 9 Me BC, 9-Methyl-β-carboline, 9-methyl-beta-carboline

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253]. It is best understood as an experimental research chemical: there are no human trials, no human pharmacokinetic or safety data, and it is not approved for human use.

    BHG Labs logo

    Lowest price

    $54.991 bottle

    at BHG Labs

    Half-life: Not characterized in humans (no pharmacokinetic data)MW: 182.22 g/mol (C12H10N2)CAS: 2521-07-56 PubMed results
    Last reviewed:

    Overview

    At A Glance

    Mechanism

    9-Me-BC is a synthetic 9-methylated -carboline (pyridoindole) alkaloid. Unlike most -carbolines, which tend to be neurotoxic, 9-Me-BC shows a distinctive dopaminergic-supportive profile in preclinical models, acting through several linked mechanisms:…

    Half-Life
    Not characterized in humans (no pharmacokinetic data).
    Dosing
    Typically once daily (morning) in community reports; frequently cycled rather than taken continuously.
    Dose Range
    Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
    Potential Benefits
    Preclinical dopaminergic support: in rodent and cell-culture studies 9-Me-BC increased tyrosine hydroxylase expression and the number of differentiated dopamine neurons [PMID:17913302, PMID:20374418]Cognitive/learning signal in rodents: 10 days of dosing improved spatial learning and raised hippocampal dopamine with dendritic and synaptic growth in rats [PMID:22380576]Neuroprotective/neurorestorative in animal Parkinson's models: restored dopamine and substantia-nigra neuron counts after MPP+ injury and boosted mitochondrial complex I activity [PMID:20360614]Anti-inflammatory and neurotrophic actions in preclinical models: reduced microglial activation and induced neurotrophic factors such as BDNF, CDNF and artemin [PMID:20374418, PMID:32285253]Community-reported (anecdotal, unverified) motivation, drive, focus and mood lift - not demonstrated in any human study
    Safety Notes
    Common
    Insomnia if dosed late in the day (anecdotal)Overstimulation, anxiety or headache at higher intakes (anecdotal)

    Overview

    9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253]. It is best understood as an experimental research chemical: there are no human trials, no human pharmacokinetic or safety data, and it is not approved for human use. Community dosing is entirely anecdotal, and because 9-Me-BC inhibits MAO-A it warrants MAOI-style caution. Research use only.

    Potential Research Fields

    Parkinson's diseaseDopaminergic neurodegenerationDepressionCognitive enhancement

    What to Expect

    • •This is a preclinical research chemical: all mechanistic and efficacy evidence comes from rodent and cell-culture work by a small number of research groups - there are zero human trials.
    • •Community users describe a stimulant-like lift in focus, motivation and mood, often the same day; these reports are anecdotal and unverified.
    • •Onset and half-life in humans are unknown, so the timing and duration of any effect cannot be stated reliably.
    • •Because it inhibits MAO-A in vitro, users treat it with MAOI-style caution: no serotonergic-drug stacking and mind tyramine-rich foods.
    • •No long-term human safety data exist - the honest expectation is uncertainty.

    Individual responses vary. Timeline based on commonly reported research observations.

    Chemical Information

    IUPAC Name

    9-methyl-9H-pyrido[3,4-b]indole

    CAS Number

    2521-07-5

    Molecular Formula

    C12H10N2

    Molecular Mass

    182.22 g/mol

    Dosing & Protocols

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • Route and how often
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Research

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    Interactions

    Interaction Matrix

    Contraindications

    Precautionary (there is no human data to define true contraindications): avoid combining with SSRIs, SNRIs, MAOIs, other serotonergic drugs, or sympathomimetic stimulants due to 9-Me-BC's in-vitro MAO-A inhibition and the theoretical serotonin-toxicity / hypertensive (tyramine) risk. Not for use in pregnancy or breastfeeding, in anyone with significant cardiovascular or hepatic disease, or alongside prescription medications, given the complete absence of human safety testing. Research use only - not for human consumption.

    Research Disclaimer

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Best Price

    $54.99

    Best $/mg

    —

    Vendors

    1

    Listings

    1

    capsule

    Form
    Sort
    Vendor Product Form Qty Price $/mg Coupon
    BHG Labs logo
    BHG Labs
    70
    🇺🇸US
    9-Me-BC capsule 1 bottle● In Stock $54.99BEST —

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with 9-Me-BC (9-Methyl-β-carboline).

    Current low
    $54.99
    current listings
    7-day low
    —
    not enough history yet
    30-day low
    —
    not enough history yet
    30-day change
    —
    not enough history yet

    Tracking since Jul 1, 2026 · 1 data point

    Vendors Selling 9-Me-BC (9-Methyl-β-carboline)

    How we score these vendors

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.

    View Scorecard

    Related Compounds

    View All

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    Fasoracetam (NS-105)

    NootropicsPhase 2

    Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.

    t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039).
    PreclinicalView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for 9-Me-BC (9-Methyl-β-carboline)

    Lowest Price

    BHG Labs logo

    BHG Labs

    $54.99

    1 vendor · 1 listing

    Research Score

    61

    6 PubMed results

    Quality Indicators

    Data Completeness

    100%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Results
    Interactions
    Vendor Listings

    Research Volume

    6PubMed results

    Limited research available

    Quick Facts

    Half-Life

    Not characterized in humans (no pharmacokinetic data).

    Molecular Weight

    182.22 g/mol

    CAS Number

    2521-07-5

    Trial Phase

    Preclinical

    Safety Profile

    Moderate Risk

    Common Side Effects

    • • Insomnia if dosed late in the day (anecdotal)
    • • Overstimulation, anxiety or headache at higher intakes (anecdotal)

    Stop Use If

    • Do not combine with SSRIs, SNRIs, MAOIs, MDMA or other serotonergic drugs
    • Avoid in pregnancy/breastfeeding and with cardiovascular or liver disease
    • Discontinue and seek care if signs of serotonin toxicity (agitation, rapid heartbeat, high temperature, tremor) occur

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    Is 9-Me-BC safe for humans?

    Unknown. There are no human safety studies, no clinical trials and no human pharmacokinetic data - every safety statement about 9-Me-BC is extrapolated from rodent/cell-culture work or from community anecdote. It is a research chemical (RUO), not an approved supplement or drug.

    Is 9-Me-BC an MAO inhibitor?

    In vitro, yes - it inhibits MAO-A with an IC50 around 1 uM and MAO-B around 15.5 uM [PMID:32285253]. That potency is why the community treats it with MAOI-style caution: avoid stacking it with SSRIs/SNRIs, other MAOIs or serotonergic supplements, and be mindful of tyramine-rich (aged/fermented) foods. These interactions are theoretical for 9-Me-BC specifically - they have not been formally documented in people.

    What does the research actually show?

    Dopaminergic, neuroprotective, neurorestorative and anti-inflammatory effects in rodents and cell cultures - including improved spatial learning and higher hippocampal dopamine in rats [PMID:22380576] and restoration of dopamine neurons in an MPP+ Parkinson's model [PMID:20360614]. None of this has been reproduced in humans, so it cannot be assumed to translate.

    How do people dose it?

    Anecdotally, roughly 5-25 mg once daily by mouth, usually in the morning and often cycled rather than taken continuously. There is no validated human dose - these figures come from nootropic forums, not clinical dosing studies.

    Can I take it with my antidepressant?

    You should not combine 9-Me-BC with SSRIs, SNRIs, MAOIs or other serotonergic medications. Because it inhibits MAO-A in vitro, combining it with serotonergic drugs carries a theoretical risk of serotonin toxicity. Talk to a clinician; do not self-combine.

    Is 9-Me-BC approved or legal as a supplement?

    No. It is not an approved drug or dietary supplement and is sold only as a research chemical for laboratory use (RUO). Legal status varies by country.

    Research Tools

    Related Compounds

    View All

    Aniracetam

    NootropicsApproved (Italy)

    Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.

    t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
    PreclinicalView Profile

    Bemethyl (bemitil)

    NootropicsApproved (Russia)

    Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.

    t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
    PreclinicalView Profile

    Bromantane

    NootropicsRussia Approved

    Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.

    34 PubMedView Profile

    Cyclazodone

    NootropicsPreclinical

    Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.

    PreclinicalView Profile

    Dihexa

    NootropicsPreclinical

    Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.

    t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
    1 PubMedView Profile

    Fasoracetam (NS-105)

    NootropicsPhase 2

    Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.

    t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039).
    PreclinicalView Profile

    Research Benches

    Reference pages that put 9-Me-BC (9-Methyl-β-carboline) next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.